Women informed of over-detection risk less likely to want mammography
the ONA take:
According to a new study published in the journal The Lancet, researchers have found that women who are better informed about the risk of over-detection and over-diagnosis associated with mammography screening are less likely to have a breast cancer screening.
Mammography screening can prevent deaths associated with breast cancer, but most women are unaware that the screening can lead to over-diagnosis and overtreatment.
For the study, researchers randomly assigned 879 women aged 48-50 years who were about to become candidates for mammography screening to receive decision support materials with or without over-detection information.
Results showed that compared with controls, more women provided with over-detection information had adequate knowledge about breast cancer screening and made an informed choice about whether to be screened, had less favorable attitudes towards breast cancer screening, and had fewer intentions to be screened for breast cancer.
The findings suggest the importance of giving women clear decision support materials so that they can make more informed decisions about whether they should receive a mammography screening.
Women who are better informed about the risk of over-detection are less likely to have a breast cancer screening.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|